Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects

Description

The purpose of this study is three-fold. First, researchers will assess whether subjects who have clinically abnormal reactions to sunlight (photosensitivity) have increased levels of microvesicle particles (MVP) following ultraviolet B (UVB) treatment to localized area of skin. Second, researchers will assess if topical application of the medicine imipramine will block UVB-induced MVP release. Third, researchers will assess if the topical cream will block UVB-induced increased erythema reactions (reddening of the skin).

Conditions

Photosensitivity, Microvesicle Particle

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is three-fold. First, researchers will assess whether subjects who have clinically abnormal reactions to sunlight (photosensitivity) have increased levels of microvesicle particles (MVP) following ultraviolet B (UVB) treatment to localized area of skin. Second, researchers will assess if topical application of the medicine imipramine will block UVB-induced MVP release. Third, researchers will assess if the topical cream will block UVB-induced increased erythema reactions (reddening of the skin).

Pilot Studies Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects

Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects

Condition
Photosensitivity
Intervention / Treatment

-

Contacts and Locations

Fairborn

Wright State Physicians, Fairborn, Ohio, United States, 45324

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Female and Male adult subjects age 18 to 50
  • * Must be able to give informed consent
  • * Have access to stable transportation
  • * All skin types on Fitzpatrick Scale (Type I-VI)
  • * Self-Identified photosensitivity
  • * Able to provide medical history and list of medications-control subjects will not be allowed to be taking a medication that is known to be photosensitizer.
  • * Underlying diseases that could affect wound healing (e.g., uncontrolled diabetes mellitus)
  • * Taking medications that are known photosensitizers (e.g., doxycycline) or anti-inflammatories (e.g., NSAIDS \[except for low-dose aspirin\] or steroids)
  • * Utilizing imipramine or any other tricyclic antidepressant (oral or cream)
  • * Utilizing topical anti-inflammatory or systemic agents (e.g., prednisone)
  • * Large tattoos in the designated testing areas
  • * Tanning bed use within last 3 months
  • * Photodynamic Therapy or UVB treatments in past 3 months
  • * Female Subjects: pregnant or nursing
  • * History of abnormal scarring (i.e., keloids)

Ages Eligible for Study

18 Years to 50 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Wright State University,

Jeffrey B Travers, MD, PhD, PRINCIPAL_INVESTIGATOR, Wright State University

Study Record Dates

2026-12